Literature DB >> 17462077

Viral vector vaccines make memory T cells against malaria.

Arturo Reyes-Sandoval1, John T Harty, Stephen M Todryk.   

Abstract

Vaccines that comprise attenuated viral vectors encoding antigens from target pathogens generate potent T-cell responses. One such pathogen is malaria, and in particular the liver stage of its life cycle. Immunogenicity and efficacy studies in animals and humans have revealed the generation of memory T cells of both the central and effector phenotypes, depending on the viral vectors used in the malaria vaccination regime (viral species and serotype, combination and sequence for prime-boost) and suggest a divergence in their protective role. Being able to influence the memory T-cell make-up in a rational manner may allow us to develop more efficacious vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17462077      PMCID: PMC2265939          DOI: 10.1111/j.1365-2567.2006.02552.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  55 in total

1.  Linear differentiation of cytotoxic effectors into memory T lymphocytes.

Authors:  J T Opferman; B T Ober; P G Ashton-Rickardt
Journal:  Science       Date:  1999-03-12       Impact factor: 47.728

2.  Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.

Authors:  Alexandre Harari; Florence Vallelian; Pascal R Meylan; Giuseppe Pantaleo
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

3.  Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance.

Authors:  Anne C Moore; Awen Gallimore; Simon J Draper; Katherine R Watkins; Sarah C Gilbert; Adrian V S Hill
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

4.  Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

Authors:  C F Ockenhouse; P F Sun; D E Lanar; B T Wellde; B T Hall; K Kester; J A Stoute; A Magill; U Krzych; L Farley; R A Wirtz; J C Sadoff; D C Kaslow; S Kumar; L W Church; J M Crutcher; B Wizel; S Hoffman; A Lalvani; A V Hill; J A Tine; K P Guito; C de Taisne; R Anders; W R Ballou
Journal:  J Infect Dis       Date:  1998-06       Impact factor: 5.226

5.  Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.

Authors:  Helen McShane; Ansar A Pathan; Clare R Sander; Sheila M Keating; Sarah C Gilbert; Kris Huygen; Helen A Fletcher; Adrian V S Hill
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

6.  Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge.

Authors:  L W Church; T P Le; J P Bryan; D M Gordon; R Edelman; L Fries; J R Davis; D A Herrington; D F Clyde; M J Shmuklarsky; I Schneider; T W McGovern; J D Chulay; W R Ballou; S L Hoffman
Journal:  J Infect Dis       Date:  1997-04       Impact factor: 5.226

7.  Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

Authors:  Caroline L Smith; P Rod Dunbar; Fareed Mirza; Michael J Palmowski; Dawn Shepherd; Sarah C Gilbert; Pierre Coulie; Joerg Schneider; Eric Hoffman; Robert Hawkins; Adrian L Harris; Vincenzo Cerundolo
Journal:  Int J Cancer       Date:  2005-01-10       Impact factor: 7.396

8.  Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

Authors:  Jenni M Vuola; Sheila Keating; Daniel P Webster; Tamara Berthoud; Susanna Dunachie; Sarah C Gilbert; Adrian V S Hill
Journal:  J Immunol       Date:  2005-01-01       Impact factor: 5.422

9.  Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria.

Authors:  Sheila M Keating; Philip Bejon; Tamara Berthoud; Jenni M Vuola; Stephen Todryk; Daniel P Webster; Susanna J Dunachie; Vasee S Moorthy; Samuel J McConkey; Sarah C Gilbert; Adrian V S Hill
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

10.  Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection.

Authors:  Michael Walther; Jon Eric Tongren; Laura Andrews; Daniel Korbel; Elizabeth King; Helen Fletcher; Rikke F Andersen; Philip Bejon; Fiona Thompson; Susanna J Dunachie; Fanny Edele; J Brian de Souza; Robert E Sinden; Sarah C Gilbert; Eleanor M Riley; Adrian V S Hill
Journal:  Immunity       Date:  2005-09       Impact factor: 31.745

View more
  10 in total

1.  Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection.

Authors:  Eiji Takayama; Takeshi Ono; Elena Carnero; Saori Umemoto; Yoko Yamaguchi; Atsuhiro Kanayama; Takemi Oguma; Yasuhiro Takashima; Takushi Tadakuma; Adolfo García-Sastre; Yasushi Miyahira
Journal:  Int J Parasitol       Date:  2010-07-08       Impact factor: 3.981

2.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

Review 3.  Applications and challenges of multivalent recombinant vaccines.

Authors:  Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

Review 4.  Salmonella enterica serovar Typhi live vector vaccines finally come of age.

Authors:  James E Galen; Marcela F Pasetti; Sharon Tennant; Patricia Ruiz-Olvera; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Cell Biol       Date:  2009-05-05       Impact factor: 5.126

5.  Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity.

Authors:  Arturo Reyes-Sandoval; Christine S Rollier; Anita Milicic; Karolis Bauza; Matthew G Cottingham; Choon-Kit Tang; Matthew D Dicks; Dong Wang; Rhea J Longley; David H Wyllie; Adrian V S Hill
Journal:  Mol Ther       Date:  2012-02-21       Impact factor: 11.454

6.  Modeling the effect of boost timing in murine irradiated sporozoite prime-boost vaccines.

Authors:  Cristina Fernandez-Arias; Clemente F Arias; Min Zhang; Miguel A Herrero; Francisco J Acosta; Moriya Tsuji
Journal:  PLoS One       Date:  2018-01-12       Impact factor: 3.240

7.  STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines.

Authors:  Eriko Padron-Regalado; Marta Ulaszewska; Alexander D Douglas; Adrian V S Hill; Alexandra J Spencer
Journal:  Sci Rep       Date:  2022-08-24       Impact factor: 4.996

8.  Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).

Authors:  Matthew G Cottingham; Rikke F Andersen; Alexandra J Spencer; Saroj Saurya; Julie Furze; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2008-02-20       Impact factor: 3.240

9.  A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.

Authors:  Amy R Noe; Diego Espinosa; Xiangming Li; Jordana G A Coelho-Dos-Reis; Ryota Funakoshi; Steve Giardina; Hongfan Jin; Diane M Retallack; Ryan Haverstock; Jeffrey R Allen; Thomas S Vedvick; Christopher B Fox; Steven G Reed; Ramses Ayala; Brian Roberts; Scott B Winram; John Sacci; Moriya Tsuji; Fidel Zavala; Gabriel M Gutierrez
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

10.  Design and evaluation of the immunogenicity and efficacy of a biomimetic particulate formulation of viral antigens.

Authors:  Victor Riitho; Adam A Walters; Satyanarayana Somavarapu; Benjamin Lamp; Till Rümenapf; Thomas Krey; Felix A Rey; Ernesto Oviedo-Orta; Graham R Stewart; Nicolas Locker; Falko Steinbach; Simon P Graham
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.